Specify a stock or a cryptocurrency in the search bar to get a summary
Aslan Pharmaceuticals Ltd ADR
ASLNASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore. Address: 83 Clemenceau Avenue, Singapore, Singapore, 239920
Analytics
WallStreet Target Price
16 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ASLN
Dividend Analytics ASLN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ASLN
Stock Valuation ASLN
Financials ASLN
Results | 2019 | Dynamics |